药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tiludronic acid
Caplacizumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Caplacizumab.
Tiludronic acid
TB-402
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with TB-402.
Tiludronic acid
IPH 2101
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with IPH 2101.
Tiludronic acid
Olaratumab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olaratumab.
Tiludronic acid
Glembatumumab vedotin
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Glembatumumab vedotin.
Tiludronic acid
Leronlimab
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Leronlimab.
Tiludronic acid
CT-011
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with CT-011.
Tiludronic acid
MYO-029
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with MYO-029.
Tiludronic acid
RI 624
The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with RI 624.
Tiludronic acid
TNX-901
The risk or severity of adverse effects can be increased when TNX-901 is combined with Inotuzumab ozogamicin.
Tiludronic acid
PRO-542
The risk or severity of adverse effects can be increased when PRO-542 is combined with Inotuzumab ozogamicin.
Tiludronic acid
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Veltuzumab
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Farletuzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Enokizumab
The risk or severity of adverse effects can be increased when Enokizumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Iratumumab
The risk or severity of adverse effects can be increased when Iratumumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Inotuzumab ozogamicin.
Tiludronic acid
Otelixizumab
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Inotuzumab ozogamicin.
Tiludronic acid
Briakinumab
The risk or severity of adverse effects can be increased when Briakinumab is combined with Inotuzumab ozogamicin.